Societal CDMO (SCTL) 10-K 1 Mar 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 22, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	Societal CDMO, Inc.
Entity Central Index Key	0001588972
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		84,892,194
Entity Shell Company	false
Entity Public Float	$ 42.2
Entity Small Business	true
Entity Emerging Growth Company	false
Trading Symbol	SCTL
Entity File Number	001-36329
Entity Tax Identification Number	26-1523233
Entity Address, Address Line One	1 E. Uwchlan Ave, Suite 112
Entity Address, City or Town	Exton
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19341
City Area Code	770
Local Phone Number	534-8239
Entity Incorporation, State or Country Code	PA
Document Annual Report	true
Document Transition Report	false
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, par value $0.01
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant’s proxy statement for the 2023 annual meeting of shareholders to be filed no later than 120 days after the end of the registrant’s fiscal year ended December 31, 2022 .
Auditor name	KPMG LLP
Auditor location	Philadelphia, PA
Auditor firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 14,995	$ 25,217
Accounts receivable, net	15,950	11,913
Contract assets	8,724	8,565
Inventory	10,301	8,917
Prepaid expenses and other current assets	2,848	2,917
Assets held for sale	2,768	0
Total current assets	55,586	57,529
Property, plant and equipment, net	50,365	51,708
Operating lease asset	5,491	5,924
Intangible assets, net	2,928	3,833
Goodwill	41,077	41,077
Other assets	1,996	246
Total assets	157,443	160,317
Current liabilities:
Accounts payable	1,466	2,085
Current portion of debt	7,577	2,039
Current portion of operating lease liability	1,079	1,055
Accrued expenses and other current liabilities	12,686	12,556
Total current liabilities	22,808	17,735
Debt, net of current portion	30,967	95,496
Operating lease liability, net of current portion	4,584	4,932
Other liabilities	39,225	90
Total liabilities	97,584	118,253
Commitments and contingencies (note 7)
Shareholders’ deficit:
Convertible preferred stock, $0.01 par value. 10,000,000 shares authorized, 450,000 shares issued and outstanding at December 31, 2022, none issued or outstanding at December 31, 2021	4,350	0
Common stock, $0.01 par value. 95,000,000 shares authorized, 84,588,868 and 46,681,453 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	846	467
Additional paid-in capital	320,298	287,351
Accumulated deficit	(265,635)	(245,754)
Total shareholders equity	59,859	42,064
Total liabilities and shareholders equity (deficit)	$ 157,443	$ 160,317

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	10,000,000	10,000,000
Shares of convertible preferred stock issued	450,000	0
Convertible preferred stock, shares outstanding	450,000	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	84,588,868	46,681,453
Common stock, shares outstanding	84,588,868	46,681,453

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 90,214	$ 75,360	$ 66,499
Operating expenses:
Cost of sales (excluding amortization of intangible assets)	67,076	55,537	54,134
Selling, general and administrative	21,954	18,374	18,124
Amortization of intangible assets	905	1,037	2,583
Total operating expenses	89,935	74,948	74,841
Operating income (loss)	279	412	(8,342)
Interest expense	(14,059)	(15,134)	(19,159)
(Loss) gain on extinguishment of debt	(4,996)	3,352	0
Loss before income taxes	(18,776)	(11,370)	(27,501)
Income tax expense	1,105	0	0
Net loss	$ (19,881)	$ (11,370)	$ (27,501)
Earnings Per Share [Abstract]
Earnings Per Share, Basic	$ 0.34	$ (0.26)	$ (1.16)
Earnings Per Share, Diluted	$ 0.34	$ (0.26)	$ (1.16)
Weighted average common shares outstanding, basic	57,877,920	44,117,473	23,744,313
Weighted average common shares outstanding, diluted	57,877,920	44,117,473	23,744,313

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Preferred Stock [Member] Convertible preferred stock [Member]	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2019	$ (6,712)		$ 233	$ 199,938	$ (206,883)
Balance, Shares at Dec. 31, 2019			23,312,928
Issuance of stock, net of costs amount	10,733		$ 47	10,686
Issuance of stock, net of costs, Shares			4,690,972
Stock-based compensation expense	10,068			10,068
Exercise of stock options, net	274		$ 1	273
Exercise of stock options, net, Shares			142,669
Vesting of restricted stock units, net	(1,136)		$ 5	(1,141)
Vesting of restricted stock units, net, Shares			454,789
Revaluation of warrants	174			174
Net loss	(27,501)				(27,501)
Balance at Dec. 31, 2020	(14,100)		$ 286	219,998	(234,384)
Balance, Shares at Dec. 31, 2020			28,601,358
Fair value of shares issuable to former equity holders of IriSys, net of costs	20,328			20,328
Issuance of stock, net of costs amount	41,443		$ 175	41,268
Issuance of stock, net of costs, Shares			17,535,752
Stock-based compensation expense	6,514			6,514
Exercise of stock options, net, Shares			80
Vesting of restricted stock units, net	(751)		$ 6	(757)
Vesting of restricted stock units, net, Shares			544,263
Net loss	(11,370)				(11,370)
Balance at Dec. 31, 2021	42,064		$ 467	287,351	(245,754)
Balance, Shares at Dec. 31, 2021			46,681,453
Issuance of stock, net of costs amount	32,415	$ 4,350	$ 371	27,694
Issuance of stock, net of costs, Shares		450,000	37,144,455
Stock-based compensation expense	$ 5,426			5,426
Exercise of stock options, net, Shares	516		516
Vesting of restricted stock units, net	$ (165)		$ 8	(173)
Vesting of restricted stock units, net, Shares			762,444
Net loss	(19,881)				(19,881)
Balance at Dec. 31, 2022	$ 59,859	$ 4,350	$ 846	$ 320,298	$ (265,635)
Balance, Shares at Dec. 31, 2022		450,000	84,588,868

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities, continuing operations:
Net loss	$ (19,881)	$ (11,370)	$ (27,501)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities, continuing operations:
Stock-based compensation expense	5,426	6,514	10,068
Non-cash interest expense	4,845	5,815	5,510
Depreciation expense	7,413	6,531	5,964
Impairment expense	0	0	966
Amortization of intangible assets	905	1,037	2,583
Deferred income tax expense	1,015	0	0
Loss (gain) on extinguishment of debt	4,996	(3,352)	0
Changes in operating assets and liabilities:
Accounts receivable	(4,037)	(1,971)	5,356
Contract assets	(159)	(730)	1,521
Inventory	(1,384)	3,380	3,460
Prepaid expenses and other assets	305	120	4
Accrued interest	(2,278)	2,505	0
Accounts payable, accrued expenses and other liabilities	(810)	2,379	1,308
Net cash (used in) provided by operating activities, continuing operations	(3,644)	10,858	9,239
Cash flows from investing activities:
Acquisition of IriSys, net of cash required	0	(24,002)	0
Purchases of property and equipment	(8,351)	(5,289)	(7,603)
Net cash used in investing activities	(8,351)	(29,291)	(7,603)
Cash flows from financing activities:
Proceeds from issuance of stock, net of costs	33,030	32,103	11,094
Proceeds from issuance of debt	36,900	0	4,416
Proceeds from sale-leaseback liability	37,250	0	0
Payment of debt principal	(103,039)	(10,100)	(10,190)
Payment of financing costs	(2,203)	(1,362)	(310)
Net payments related to vesting of restricted stock units	(165)	(751)	(1,136)
Net proceeds related to exercise of stock options	0	0	274
Net cash provided by financing activities	1,773	19,890	4,148
Net (decrease) increase in cash and cash equivalents from continuing operations	(10,222)	1,457	5,784
Cash and cash equivalents, beginning of period	25,217	23,760	19,148
Cash and cash equivalents, end of period	14,995	25,217	23,760
Supplemental disclosures of cash flow information:
Cash flows used in operating activities, discontinued operations	0	0	(1,172)
Cash paid for interest	12,574	7,238	13,945
Purchases of property, plant and equipment included in accrued expenses and accounts payable	1,384	1,045	1,244
Deferred financing costs included in accounts payable and accrued expenses	1,359	0	0
Offering costs included in accounts payable and accrued expenses	527	0	0
Reclassification of deferred financing costs to equity	88	0	361
Fair value of shares issuable to former equity holders of IriSys	0	20,931	0
Fair value of note issued to former equity holder of IriSys	0	5,240	0
Issuance of common stock to reduce debt principal and accrued exit fees	0	6,060	0
Issuance of common stock to settle interest obligations	$ 0	$ 3,211	$ 0

Background

Background	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	(1)   Background Societal CDMO, Inc. (the “Company”) was incorporated in the Commonwealth of Pennsylvania on November 15, 2007 as Recro Pharma, Inc. Effective March 21, 2022, Recro Pharma, Inc changed its name to Societal CDMO, Inc. to reflect the corporate transformation that had taken place primarily as a result of its acquisition and successful integration of IriSys, LLC (“IriSys”) into the organization. The Company is a bi-coastal contract development and manufacturing organization with capabilities spanning pre-investigational new drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, the Company provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company has incurred net losses since inception and has an accumulated deficit of $ 265,635 as of December 31, 2022 , which is primarily related to the activities of its former research and development business, which was spun-out in 2019. The Company’s future operations are highly dependent on the profitability of its development and manufacturing operations. Management believes that it is probable that the Company will be able to meet its obligations as they become due within at least one year after the date financial statements included herein are issued.

Summary of Significant Accounti

Summary of Significant Accounting Principles	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Principles	(2)   Summary of significant accounting principles Basis of presentation and principles of consolidation The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. The Company has determined that it operates in a single segment. Reclassification The Company reclassified certain prior year amounts on the consolidated balance sheet to conform to the current year presentation. These reclassifications had no impact on the previously reported total assets, liabilities or shareholders’ equity. Use of estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Business combinations The Company measures the purchase price paid for acquired companies based on fair value and allocates that purchase price to the assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from the acquired companies and expectations of future cash flows. Costs associated with business combinations are expensed as incurred as selling, general and administrative expenses. Cash and cash equivalents Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value due to changes in interest rates. Accounts receivable, net Accounts receivable generally represent amounts billed for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for credit losses, if necessary. We apply judgment in assessing the ultimate realization of our receivables, and we estimate an allowance for credit losses based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. The allowance for credit losses was not material as of the balance sheet dates presented. Inventory Inventory is stated at the lower of cost or net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Items are issued out of inventory using the first-in, first-out method. Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns. Property, plant and equipment, net Property, plant and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture, office and computer equipment; six to ten years for manufacturing equipment; 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. The Company reviews the carrying value of property, plant and equipment for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of individual assets or asset groups may not be recoverable. The Company considers assets to be held for sale when (i) management commits to a plan to sell the asset; (ii) the asset is available for immediate sale in its present condition; (iii) the asset is actively being marketed for sale at a price that is reasonable given the estimate of current market value; and (iv) the sale is probable and will be completed within one year. Upon designation of an asset as held for sale, the Company records the asset’s value at the lower of its carrying value plus selling costs or its estimated net realizable value. Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company in a business combination. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment analysis for goodwill consists of an optional qualitative assessment potentially followed by a quantitative analysis. If the Company determines that the carrying value of its reporting unit exceeds its fair value, an impairment charge is recorded for the excess. The Company performs its annual goodwill impairment test as of November 30 th , or whenever an event or change in circumstance occurs that would require reassessment of the impairment of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance, actual and anticipated changes in industry and market conditions, and competitive environments. As a result of the most recent annual goodwill impairment test, the Company determined that there was no impairment of goodwill. Definite-lived intangible assets are amortized on a straight-line basis over their estimated useful life. The Company is required to review the carrying value of definite-lived intangible assets for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Contingencies The Company’s business exposes it to various contingencies including compliance with regulations, legal exposures and other matters. Loss contingencies are reflected in the financial statements based on management's assessments of their expected outcome or resolution: • They are recognized as liabilities on the balance sheet if the potential loss is probable and the amount can be reasonably estimated. • They are disclosed if the potential loss is material and considered at least reasonably possible. Significant judgment is required to determine probability and whether the amount can be reasonably estimated. Due to uncertainties related to these matters, accruals are based only on the information available at the time. As additional information becomes available, the Company reassesses potential liabilities and may revise previous estimates. Revenue recognition The Company generates revenues from manufacturing, packaging, research and development and related services for multiple pharmaceutical companies. Manufacturing Manufacturing and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include variable consideration such as pricing and volume-based adjustments. Profit-sharing In addition to manufacturing and packaging revenue, certain customers who use our technologies are subject to agreements that provide us intellectual property sales-based profit-sharing and/or royalties consideration, collectively referred to as profit-sharing, computed on the net product sales of the commercial partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. The Company has determined that in its arrangements, the license for intellectual property is not the predominant item to which the profit-sharing relates, so the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by the Company’s commercial partners, which are outside of the Company’s control. Factors causing price adjustments by the Company’s commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing. Research and development Research and development revenue includes services associated with formulation, process development, clinical trials materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms. In contracts that specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within the Company’s control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received. In contracts that require revenue recognition over time, the Company utilizes input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications, and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by the Company’s services and can make changes to its process or specifications upon request. Contract assets represent revenue recognized for performance obligations completed or in process before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. Contract liabilities represent payments received from customers prior to the completion of associated performance obligations. Concentration of credit risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are primarily concentrated among two customers with balances of 64 %. If any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition. The Company is dependent on its relationships with a small number of commercial partners. The Company’s four largest customers generated 77 % of revenues in 2022 while the Company’s three largest customers generated 82 % of revenues in 2021 . Stock-based compensation expense The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur. Determining the appropriate fair value of stock options requires the use of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” which is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Upon exercise of stock options or vesting of restricted stock units, the holder may elect to cover tax withholdings by forfeiting shares of an equivalent value. In such cases, the Company issues net new shares to the holder, pays the tax withholding on behalf of the participant and presents the payment similar to a capital distribution: a reduction to additional paid-in-capital and a financing cash outflow in the consolidated financial statements. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. In assessing the realizability of net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. A full valuation allowance was recorded as of December 31, 2022 and December 31, 2021. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year. Leases The Company determines under U.S. GAAP if an arrangement is a lease at inception. The arrangement is a lease if it conveys the right to the Company to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Options to extend the lease are included in the lease term if the options are reasonably certain to be exercised. Operating lease expense is recognized on a straight-line basis over the lease term. In a sale-leaseback transaction, the Company determines under U.S. GAAP if the transaction meets the requirements of a sale and purchase. If the Company determines that it did not relinquish control of the assets to the buyer-lessor, it does not qualify for sale-leaseback accounting. Operating lease balances are presented as separate captions on the balance sheets. Finance lease assets are included in property, plant and equipment. Finance lease liabilities are included in other liabilities. Income or loss per share Net loss per common share is computed using the two-class method required due to the participating nature of the Series A Convertible Preferred Stock (as defined and discussed in note 10) given the rights to participate in dividends if declared on common stock. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders. In addition, as these securities are participating securities, the Company is required to calculate diluted net income or loss per share under the if-converted and treasury stock method in addition to the two-class method and utilize the most dilutive result. In periods where there is a net loss, no allocation of undistributed net loss to the Series A Convertible Preferred stockholders is performed as the holders of these securities are not contractually obligated to participate in the Company’s losses. Basic income or loss per share is determined by dividing net income or loss (the numerator) by the weighted average common shares outstanding during the period (the denominator). Additionally, the weighted average common shares outstanding for the year ended December 31, 2021 include 9,302,718 shares issuable to the former equity holders of IriSys, since the acquisition date. To calculate diluted income or loss per share, the numerator and denominator are adjusted to eliminate the income or loss and the dilutive effects on shares, respectively, caused by outstanding common stock options, warrants and unvested restricted stock units, using the treasury stock method, if the inclusion of such instruments would be dilutive. For all years presented, the Company incurred a net loss. In periods of net loss, the inclusion of dilutive securities would be antidilutive because it would reduce the amount of loss incurred per share. As a result, no additional dilutive shares were included in diluted loss per share, and there were no differences between basic and diluted loss per share. The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share: Year ended December 31, 2022 2021 2020 Restricted stock units 1,583,469 731,525 684,852 Stock options 7,317,274 4,645,109 3,577,605 Warrants 362,030 348,664 348,664 Amounts in the table above reflect the common stock equivalents of the noted instruments.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	(3)   Inventory The following table presents the components of inventory: December 31, 2022 December 31, 2021 Raw materials $ 4,318 $ 3,038 Work in process 3,689 3,363 Finished goods 2,294 2,516 Inventory $ 10,301 $ 8,917

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	(4)  Goodwill and other i ntangible assets The following table presents the rollforward of goodwill: Balance, December 31, 2020 $ 4,319 Acquisition of IriSys 36,758 Balance, December 31, 2021 and 2022 $ 41,077 The following table presents the components of other intangible assets: December 31, 2022 December 31, 2021 Gross value Accumulated amortization Carrying value Gross value Accumulated amortization Carrying value Customer relationships $ 18,900 $ 16,188 $ 2,712 $ 18,900 $ 15,685 $ 3,215 Backlog 460 261 199 460 73 387 Trademarks and tradenames 310 293 17 310 79 231 Total $ 19,670 $ 16,742 $ 2,928 $ 19,670 $ 15,837 $ 3,833 The following table presents estimated future amortization of other intangible assets: Twelve months ending December 31, 2023 $ 687 2024 501 2025 486 2026 486 2027 486 Thereafter 282 Total $ 2,928

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	(5)   Property, plant and equipment, net The following table presents the components of property, plant and equipment : December 31, 2022 December 31, 2021 Land $ 604 $ 3,263 Building and improvements 22,751 22,717 Furniture, office and computer equipment 6,388 6,213 Manufacturing equipment 58,039 49,687 Construction in process 7,024 6,856 Property, plant and equipment, gross 94,806 88,736 Less: accumulated depreciation ( 44,441 ) ( 37,028 ) Property, plant and equipment, net $ 50,365 $ 51,708 Interest expense capitalized to construction in process was $ 1,195 in 2022 and $ 424 in 2021. In September 2022, the Company signed a sales and purchase agreement to sell approximately 121 acres of land adjacent to its Gainesville, Georgia manufacturing campus for expected proceeds of $ 9,075 . The land was determined to be held for sale at December 31, 2022 and reclassified at cost to other current assets with a carrying value of $ 2,659 . The sale of the land is subject to customary closing conditions for transactions of this type, including completion of title and environmental due diligence and receipt of certain zoning approvals and permits, which remained to be satisfied at December 31, 2022. In December 2022 , the Company sold its commercial manufacturing campus in Gainesville, Georgia for a purchase price of $ 39,000 and the Company entered into a lease agreement under which the Company agreed to lease back the property for an initial term of 20 years. The Company determined that it did not relinquish control of the assets to the buyer-lessor. Therefore, the Company accounted for the transactions as failed sale-leaseback whereby the Company continues to depreciate the assets and recorded a financing obligation for the consideration received from the buyer-lessor. See note 9 for additional information.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	(6)   Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: December 31, 2022 December 31, 2021 Payroll and related costs $ 4,276 $ 5,717 Accrued transaction costs 3,653 — Contract liabilities (see note 11) 2,211 2,308 Property, plant and equipment 934 663 Professional and consulting fees 356 552 Accrued interest 227 2,505 Other 1,029 811 Total $ 12,686 $ 12,556 Accrued transaction costs include costs incurred related to the refinancing completed in December 2022 which included the sale and subsequent leaseback of the Company’s commercial manufacturing campus located in Gainesville, Georgia (see note 9), the issuance of common and preferred stock, a borrowing of $ 36,900 under a new term loan with Royal Bank of Canada (see note 8) and a one-time cash transaction bonus.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(7)   Commitments and contingencies Litigation The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. Except as disclosed below, the Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition or results of operations. On May 31, 2018, a securities class action lawsuit was filed against the Company and certain of its officers and directors (collectively, the “Defendants”) in the U.S. District Court for the Eastern District of Pennsylvania (the “Court”) (Case No. 2:18-cv-02279-MMB) that purported to state a claim for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, based on statements made by the Company concerning the New Drug Application (“NDA”) for IV meloxicam. The complaint sought unspecified damages, interest, attorneys’ fees and other costs. In December 2022, a settlement was reached in the litigation, and the costs of the settlement were covered by Baudax Bio, Inc. pursuant to the terms of the separation agreement covering the spin-out of Baudax Bio, Inc. from our business in 2019. On July 2, 2022, a product liability lawsuit was filed against the Company and various other defendants in the State Court of Cobb County, Georgia that claimed injuries and damages caused by Plaintiff Jakob Cuble’s alleged ingestion of, among other things, Focalin XR. The complaint seeks compensatory and punitive damages. On July 7, 2022, and prior to the Company being served with the Complaint, a co-defendant removed the matter to the United States District Court for the Northern District of Georgia, Atlanta Division. The Company filed its responsive pleading on August 2, 2022. In September 2022, the case was remanded to the State Court of Cobb County, Georgia, where it presently pends. The Company believes that the lawsuit is without merit and intends to vigorously defend against it. Purchase commitments As of December 31, 2022, the Company had outstanding cancelable and non-cancelable purchase commitments in the aggregate amount of $ 9,732 related to inventory, capital expenditures and other goods and services. Employment agreements and certain other contingencies The Company has entered into employment agreements with each of its named executive officers that provide for, among other things, severance commitments of up to $ 1,303 should the Company terminate the named executive officers for convenience or if certain events occur following a change in control. In addition, the Company is subject to other contingencies of up to $ 3,772 in the aggregate if certain events occur following a change in control.

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	(8)   Debt The following table presents the components and classification of debt: December 31, 2022 December 31, 2021 Debt principal: Term loan under Credit Agreement $ 36,900 $ — Term loans with Athyrium — 100,000 Note with former equity holder of IriSys 4,078 6,117 Other 339 339 Debt principal 41,317 106,456 Debt adjustments: Unamortized deferred issuance costs ( 2,476 ) — Unamortized deferred issuance costs with Athyrium — ( 8,896 ) Exit fee accretion — 669 Unamortized original discount ( 297 ) ( 694 ) Carrying value of debt $ 38,544 $ 97,535 Current portion of debt $ 7,577 $ 2,039 Debt, net of current portion 30,967 95,496 Carrying value of debt $ 38,544 $ 97,535 The following table presents the future maturity of debt principal: Twelve months ending December 31, 2023 $ 7,577 2024 4,823 2025 28,626 2026 39 2027 46 Thereafter 206 Total debt principal $ 41,317 Term loan under Credit Agreement The Company is currently party to a credit agreement (the “Credit Agreement”) with Royal Bank of Canada. The Credit Agreement has been fully drawn in the form of a term loan of $ 36,900 . The outstanding principal amount will be repaid in equal quarterly payments totaling $ 1,845 in 2023, $ 2,768 in 2024 and $ 3,690 in 2025, with the remaining principal balance due December 16, 2025. If the Company completes a sale of certain real property by December 14, 2023 and makes the $ 10,000 principal repayment disclosed below, the quarterly principal payments will be reduced proportionately to the reduction in principal . Subject to certain exceptions, the Company is required to make mandatory prepayments with the cash proceeds received in respect of asset sales, extraordinary receipts and debt issuances, upon a change of control and specified other events. Additionally, the Company is obligated to repay $ 10,000 of principal by December 14, 2023 upon the sale of certain real property adjacent to its Gainesville, Georgia manufacturing campus (see note 5). If that property is not sold by December 14, 2023, the Company will be required to pay a fee of $ 369 and increase each of its quarterly principal payments by $ 231 until that property is sold and the $ 10,000 principal payment is made. Because the Company concluded that the sale of the property is probable as of December 31, 2022, an additional $ 3,693 of debt principal has been presented as current, representing the carrying value of the current asset held for sale plus the $ 925 excess of the principal payment over the expected proceeds from the asset . The Credit Agreement also includes certain financial covenants that the Company will need to satisfy on a quarterly basis, including: (i) maintaining a net leverage ratio less than 3.75 :1.00, stepping down to 2.75 :1.00 over time; (ii) maintaining a fixed charge coverage ratio greater than 1.15 :1.00; and (iii) maintaining no less than $ 4,000 cash and cash equivalents on hand, stepping up to $ 5,000 over time. As of December 31, 2022, the Company was in compliance with its covenants under the Credit Agreement. In connection with the Credit Agreement, the Company has paid financing costs. These costs are being recognized in interest expense using the effective interest method over the term of the Credit Agreement, resulting in non-cash interest expense of $ 35 in 2022. The Credit Agreement bears interest at a floating rate equal to the three-month term Secured Overnight Financing Rate, or SOFR, with an initial floor of 1.00 %, plus an applicable margin that is equal to 4.50 % per annum for the first year, 5.00 % for the second year and 5.50 % for the third year, with quarterly interest payments due until maturity . At December 31, 2022, the overall effective interest rate, including cash paid for interest and non-cash interest expense, was 11.7 % . Historical term loans with Athyrium The Company was previously party to a credit agreement with Athyrium Opportunities III Acquisition LP (“Athyrium Credit Agreement”). The Athyrium Credit Agreement was fully drawn in the form of $ 100,000 of term loans at an interest rate equal to the three-month LIBOR rate, with a 1 % floor plus 8.25 % per annum and maturing on December 31, 2023 . The Company used the proceeds from the Credit Agreement, along with the proceeds from the sale-leaseback transaction (see note 9) and the issuance of preferred and common stock (see note 10) to repay in full all outstanding indebtedness under the Athyrium Credit Agreement, including accrued and unpaid interest and the required exit fee. The Athyrium Credit Agreement was amended numerous times with the Company paying various financing costs, incurring costs to record and subsequently to adjust the value of warrants issued to Athyrium (see note 10) and accreting the exit fee described above. These costs were recognized in interest expense using the effective interest method over the term of the Athyrium Credit Agreement, resulting in non-cash interest expense of $ 4,411 in 2022, $ 5,558 in 2021 and $ 5,510 in 2020. As a result of fully paying off the terms loans under the Athyrium Credit Agreement, the Company recorded a loss on extinguishment of debt of $ 4,996 for the write-off of the remaining unamortized deferred financing costs. The overall effective interest rate, including cash paid for interest and non-cash interest expense, immediately prior to repayment was 16.4 %. Note with former equity holder of IriSys In connection with the acquisition of IriSys (see note 15), the Company issued a subordinated promissory note to a former equity holder of IriSys in the aggregate principal amount of $ 6,117 (the “Note”). The Note is unsecured, has a three-year term, and bears interest at a rate of 6 % per annum. The Note must be repaid in three equal annual installments through its maturity date, August 13, 2024 . The Note may be prepaid in whole or in part at any time prior to the maturity date. The Note is expressly subordinated in right of payment and priority to the term loan under the Credit Agreement with Royal Bank of Canada. The Note was initially recognized at fair value as part of the consideration paid for the acquisition of IriSys, resulting in an original discount recognized of $ 877 that is being recognized as interest expense using the effective interest method over the term of the Note. At December 31, 2022, the overall effective interest rate, including the amortization of the original discount, was 13.0 % . The Company paid interest of $ 367 to the note holder during the year ended December 31, 2022 and has accrued interest of $ 94 in 2022 that will become payable to the former equity holder of IriSys on August 13, 2023. Other In connection with the acquisition of IriSys (see note 15), the Company assumed a loan with a principal amount of $ 339 . In May 2020, the Company entered into a $ 4,416 promissory note issued under a Federal COVID-19 relief program and shortly after prepaid $ 1,100 of principal to comply with emerging Federal guidance. The note had a two-year term and accrued interest at a rate of 1.0 % per annum, payable upon maturity. In June 2021, the Company received forgiveness of principal and interest on the note and recorded a gain on extinguishment of debt of $ 3,352 , consisting of forgiveness of $ 3,316 of principal and $ 36 of accrued interest.

Other Liabilities

Other Liabilities	12 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	(9)  Other liabilities At December 31, 2022, other liabilities include a sale-leaseback liability of $ 38,168 and other liabilities of $ 1,057 . Sale-leaseback liability In December 2022 , the Company concurrently entered into sale and lease agreements with Tenet Equity Funding SPE Gainesville, LLC (“Tenet”) related to its commercial manufacturing campus in Gainesville, Georgia. The selling price was $ 39,000 , of which $ 1,750 was retained by Tenet as a lease deposit and classified within other assets, resulting in cash proceeds to the Company of $ 37,250 in 2022. The lease is for an initial term of 20 years with four renewal options of ten years each. Rent under the lease will be payable monthly at a rate of $ 3,510 per year, increasing annually by 3 %, except for the first year where annual base rent will increase by the change in the consumer price index, not to exceed 5 %, if greater. The Company is responsible for the payment of all operating expenses, property taxes and insurance for the property. Pursuant to the terms of the lease, the Company will have a purchase option every ten years and a right of first offer and a right of first refusal to purchase the property should the buyer-lessor intend to sell the property to a third party. The Company determined that it did not relinquish control of the assets to the buyer-lessor. Therefore, the assets were not derecognized, and the selling price was recorded as a financial liability. As of December 31, 2022, the Company has recognized a liability of $ 38,168 , that is net of $ 869 of deferred financing costs. The Company will recognize interest expense at a 10.95 % imputed rate of interest over a term of 20 years . The deferred financing costs will also be amortized and recognized as interest expense using the effective interest method over the term of the lease. The gross liability balance will increase through 2034, at which point it will decrease through the end of lease term on December 31, 2042.

Shareholders' equity or deficit

Shareholders' equity or deficit	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity or Deficit	(10)   Shareholders’ equity or deficit Convertible preferred stock In December 2022, the Company issued 450,000 shares of Series A Convertible Preferred Stock for proceeds of $ 11.00 per share. Each share is convertible into ten shares of common stock automatically upon approval by the Company’s shareholders to increase the number of authorized shares of common stock. If the approval is not obtained by June 30, 2023, the conversion rate will be immediately increased by 10 % and annually thereafter until approval has been obtained. Shares of Series A Convertible Preferred Stock feature a liquidation preference over common shares, have no voting rights and are entitled to receive dividends equally with shares of common stock on an as-if-converted basis. Warrants At December 31, 2022 , warrants to purchase 402,126 shares of common stock were outstanding. The warrants are held by Athyrium, equity-classified, exercisable at $ 1.50 per share and expire in November 2024 . See note 8 for additional details.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	(11)   Revenue recognition The following table presents changes in contract assets and liabilities: Contract assets Contract liabilities Balance at December 31, 2021 $ 8,565 $ ( 2,308 ) Changes to the beginning balance arising from: Reclassification to receivables as the result of rights to consideration becoming unconditional ( 11,298 ) — Reclassification to revenue as the result of performance obligations satisfied 1,078 2,022 Changes in estimate 1,869 17 Net change to contract balance recognized since beginning of period due to recognition of revenue, amounts billed and changes in estimate 8,510 ( 1,942 ) Balance at December 31, 2022 $ 8,724 $ ( 2,211 ) Contract assets and contract liabilities are reported at the contract level. Contracts with multiple performance obligation are reported as a net contract asset or contract liability on the consolidated balance sheet. The reclassification to revenue appearing in the contract assets column results from the recognition of revenue on contract liabilities that are presented as a net contract asset at the beginning of the year . The following table disaggregates revenue by timing of revenue recognition: Year ended December 31, 2022 2021 2020 Point in time $ 70,325 $ 60,992 $ 61,616 Over time 19,889 14,368 4,883 Total $ 90,214 $ 75,360 $ 66,499 The Company’s payment terms for manufacturing revenue and development services are typically 30 to 45 days. Profit-sharing revenue is recorded to accounts receivable in the quarter that the product is sold by the commercial partner upon reporting from the commercial partner and payment terms are generally 45 days after quarter end.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Retirement Plan	(12)   Retirement Plan The Company has a voluntary 401(k) savings plan in which all employees are eligible to participate. The Company’s policy is to match 100 % of the employee contributions up to a maximum of 5 % of employee compensation. Total Company contributions to the 401(k) plan were $ 1,348 for 2022 , $ 915 for 2021 and $ 941 for 2020 .

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	(13)   Stock-based compensation In October 2013, the Company established an equity incentive plan that has been subsequently amended and restated to become the 2018 Amended and Restated Equity Incentive Plan (the “A&R Plan”). At December 31, 2022, a total of 3,237,642 shares were available for future grants under the A&R Plan. On December 1 st of each year, pursuant to an “evergreen” provision of the A&R Plan, the number of shares available under the A&R Plan may be increased by the board of directors by an amount equal to 5 % of the outstanding common stock on December 1 st of that year. Stock options Stock options are exercisable generally for a period of ten years from the date of grant and generally vest over four years . The following table presents information about the fair value of stock options granted: Year ended December 31, 2022 2021 2020 Weighted average grant date fair value $ 1.02 $ 1.77 $ 5.14 Assumptions used to determine fair value: Range of expected option life 5.5 - 6.0 years 5.5 - 6.0 years 5.5 - 6.0 years Expected volatility 79 - 81 % 79 - 81 % 75 - 81 % Risk-free interest rate 1.5 - 4.0 % 0.7 - 1.4 % 0.3 - 1.4 % Expected dividend yield — — — The intrinsic value of options exercised were negligible in 2022 and 2021 , and $ 1,058 in 2020. The following table presents information about stock option balances and activity: Number of shares Weighted average exercise price Aggregate intrinsic value Weighted average remaining contractual life Balance, December 31, 2021 5,267,567 $ 6.47 5.7 years Granted 4,055,633 1.49 Exercised ( 516 ) 1.32 Exchanged ( 668,009 ) 9.79 Forfeited or expired ( 604,338 ) 3.75 Balance, December 31, 2022 8,050,337 3.89 $ — 6.6 years Exercisable 4,054,697 6.01 — 4.4 years Included in the table above are 1,210,552 options outstanding as of December 31, 2022 that were granted outside the A&R Plan. The grants were made pursuant to the inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). The Company issued an offer to certain employees to cancel options that met defined eligibility requirements in exchange for RSUs. Pursuant to the exchange offer, the Company cancelled 668,009 stock options and granted 167,094 RSUs that will vest in two equal annual installments. Restricted stock units Restricted stock units (“RSUs”) vest over six months to four years depending on the purpose of the award and sometimes include performance conditions in addition to service conditions. The fair value of RSUs on the date of grant is measured as the closing price of the Company’s common stock on that date. The weighted average grant-date fair value of RSUs awarded to employees was $ 1.32 in 2022, $ 3.49 in 2021 and $ 5.34 in 2020. The fair value of RSUs vested was $ 897 in 2022, $ 2,663 in 2021 and $ 4,039 in 2020. The following table presents information about recent RSU activity: Number of shares Weighted average grant date fair value Balance, December 31, 2021 990,065 $ 3.63 Granted 1,552,590 1.32 Exchanged 167,094 0.80 Vested ( 587,895 ) 3.56 Forfeited ( 59,988 ) 2.44 Balance, December 31, 2022 2,061,866 1.71 Included in the table above are 77,256 time-based RSUs outstanding at December 31, 2022 that were granted outside of the A&R Plan. The grants were made pursuant to the inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). Other information The following table presents the classification of stock-based compensation expense: Year ended December 31, 2022 2021 2020 Cost of sales $ 1,868 $ 2,797 $ 3,754 Selling, general and administrative expenses 3,558 3,717 6,314 Total $ 5,426 $ 6,514 $ 10,068 For the year ended December 31, 2020, stock-based compensation expense included awards issued to the Company’s employees as well as Baudax Bio employees that provided services to the Company through the transition services agreement and certain other related agreements. In accordance with the terms of those agreements, the Societal equity grants held by such former employees continued to vest in accordance with their respective vesting schedules. Any stock-based compensation expense with respect to former employees who continue to vest based on their employment service at Baudax Bio but no longer provide services to the Company is not reflected in the Company’s financial statements. As of December 31, 2022, there was $ 7,108 of unrecognized compensation expense related to unvested options and RSUs that are expected to vest and will be expensed over a weighted average period of 2.1 years.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	(14)   Income Taxes All of the Company’s income from continuing operations is domestic. The components of the income tax provision from continuing operations are as follows: Year ended December 31, 2022 2021 2020 Current: Federal $ 33 $ — $ — State 57 — — Total current 90 — — Deferred: Federal 1,399 ( 2,396 ) ( 5,539 ) State 4,266 ( 677 ) ( 1,596 ) Total deferred 5,665 ( 3,073 ) ( 7,135 ) Change in valuation allowance ( 4,650 ) 3,073 7,135 Income tax expense $ 1,105 $ — $ — In 2022, the Company entered into a sale-leaseback transaction of its commercial manufacturing campus in Gainesville, Georgia, as discussed further in note 9. This transaction was treated as a sale for federal and state income tax purposes. The sale resulted in a taxable gain of approximately $ 25,350 that was mostly offset with net operating loss carryforwards, as discussed further below. Following application payments made in 2022, of net operating loss carryforwards and other tax attributes, the Company estimates a current tax obligation of $ 47 for tax year 2022, which is included in accrued expenses and other current liabilities on the consolidated balance sheet. The Company also recognized a deferred tax provision of $ 1,015 as discussed further below. A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate is as follows: Year ended December 31, 2022 2021 2020 U.S. federal statutory income tax rate 21 % 21 % 21 % State taxes, net of federal benefit 7 % 8 % 6 % Change in state tax rate ( 22 )% ( 2 )% — Nondeductible expenses ( 5 )% ( 1 )% ( 1 )% Research and development credits ( 23 )% 1 % — Change in valuation allowance 16 % ( 27 )% ( 26 )% Other — — — Effective income tax rate ( 6 )% — — In 2022, the Commonwealth of Pennsylvania enacted a reduction to its corporate tax rate from 9.9 % to 8.9 % in 2023. Additionally, the rate will be further reduced by 0.5 % each year until 2031 when the rate will be 4.99 %. This resulted in a revaluation of outstanding state deferred taxes and the significant rate change above. In 2022, the Company also derecognized its deferred tax assets for research and development credits as discussed further below. The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 33,352 $ 38,970 Interest expense 12,944 13,960 Sale-leaseback 9,093 — Stock-based compensation 4,681 4,459 Research and development credits — 4,581 Other 3,950 4,635 Gross deferred tax asset 64,020 66,605 Valuation allowance ( 50,909 ) ( 55,421 ) Deferred tax assets, net of valuation allowance 13,111 11,184 Deferred tax liabilities: Depreciation ( 10,750 ) ( 7,057 ) Contract assets ( 2,082 ) ( 2,346 ) Other ( 1,294 ) ( 1,781 ) Deferred tax liabilities ( 14,126 ) ( 11,184 ) Net deferred tax liabilities $ ( 1,015 ) $ — The net deferred tax liability shown in the table above is recorded in other liabilities on the consolidated balance sheet at December 31, 2022. These net liabilities result from future tax years in which settlements of deferred tax liabilities are forecasted to exceed settlements of deferred tax assets. Beginning December 31, 2022, net operating loss carryforwards that could fully offset such liabilities are no longer available because they were all utilized for the December 2022 sale-leaseback transaction, as discussed further below. The Company continues to maintain a full valuation allowance against its U.S. and state deferred tax assets based on the available positive and negative evidence available. An important aspect of objective negative evidence evaluated was the Company’s historical operating results over the prior three-year period. The Company maintains the valuation allowance as of December 31, 2022 as a result of historical losses, inclusive of discontinued operations, during the most recent three-year period. The Company will re-evaluate the need for a valuation allowance in future periods based on its operating results as a standalone entity. The following table summarizes carryforwards of net operating losses as of December 31, 2022: Amount Expiration Federal net operating losses, 2008 to 2017 $ 76 2028 Federal net operating losses, 2018 to 2022 125,501 No expiration State net operating losses 135,420 2028 – 2042 Under U.S. federal tax law, the utilization of a corporation’s net operating loss and research and development tax credit carryforwards is limited following a greater than 50 % change in ownership during a three-year period. Any unused annual limitation may be carried forward to future years for the balance of the carryforward period. The Company has determined that it experienced ownership changes, as defined by the Act, during the 2008, 2014, 2016 and 2022 tax years; accordingly, the Company’s ability to utilize the aforementioned carryforwards is subject to various annual limitations. As a result of the 2022 ownership change, the Company further determined its research and development tax credits would not be available in future periods, so the related deferred tax assets were written off in 2022. State net operating loss carryforwards may be further limited, including in Pennsylvania, which has a limitation of 40 % of taxable income after modifications and apportionment on state net operating losses utilized in any one year. At December 31, 2022 , the Company had no accrued interest or penalties related to uncertain tax positions, and no amounts have been recognized in the Company’s statements of operations. Due to net operating loss and tax credit carry forwards that remain unutilized, income tax returns for tax years since inception remain subject to examination by the taxing jurisdictions.

Acquisition of IriSys

Acquisition of IriSys	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Acquisition of IriSys	(15)   Acquisition of IriSys On August 13, 2021 , the Company acquired all of the units of IriSys pursuant to a unit purchase agreement. IriSys provides contract pharmaceutical product development and manufacturing services, specializing in formulation research and development and good manufacturing practices of clinical trial materials and specialty pharmaceutical products. The acquisition advances the Company’s ongoing growth strategy and leads to key synergies within business development, clinical development and commercial scale-up, as well as a strong cultural alignment and fit between the companies. The aggregate purchase price consideration was comprised of cash consideration, a subordinated promissory note and a contractual obligation to issue 9,302,718 shares of the Company’s common stock, which were issued on February 14, 2022. The following table summarizes the consideration paid: August 13, 2021 Cash paid, net of cash acquired $ 24,002 Net working capital adjustment receivable ( 417 ) Fair value of shares issuable to former equity holders of IriSys 20,931 Fair value of note with former equity holder of IriSys 5,240 Total estimated consideration $ 49,756 The fair value of the shares issuable was determined by using the price of the Company’s common stock on the acquisition date, less a discount for lack of marketability due to the shares being unregistered shares of the Company. The fair value of the note was determined using a discounted cash flow analysis that incorporated an estimate of the market interest rate for debt of similar terms and credit risk on the acquisition date. The Company incurred $ 1,211 in transaction costs related to the acquisition that were expensed as incurred and classified as selling, general and administrative expenses. The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition: As of August 13, 2021 Assets acquired: Accounts receivable $ 909 Contract assets 505 Inventory 685 Prepaid expenses and other current assets 91 Property and equipment 9,304 Operating lease asset 5,648 Intangible assets 4,170 Goodwill 36,758 Other assets 146 Total assets acquired $ 58,216 Liabilities assumed: Accounts payable $ 730 Accrued expenses and other current liabilities 1,556 Operating lease liability 5,648 Debt from finance loan 339 Other liabilities 187 Total liabilities assumed $ 8,460 Net assets acquired $ 49,756 The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition date estimated fair values. The identifiable intangible assets are subject to amortization on a straight-line basis. The following table presents information about the acquired identifiable intangible assets: Fair value Weighted average amortization period Customer relationships $ 3,400 7.0 years Backlog 460 2.4 years Trademarks and tradenames 310 1.5 years Total $ 4,170 6.1 years The fair value of property, plant and equipment was determined using a cost approach valuation method. The customer relationships and acquired backlog were valued using the multi-period excess earnings method and trademarks and trade names were valued using the relief from royalty method. These methods require several judgments and assumptions to determine the fair value of intangible assets, including revenue growth rates, discount rates, EBITDA margins, and tax rates, among others. These nonrecurring fair value measurements are Level 3 measurements within the fair value hierarchy. Goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired. The goodwill related to the acquisition was attributable to expected synergies, the value of the assembled workforce as well as the collective experience of the management team with regards to its operations, customers, and industry. The goodwill is deductible for tax purposes. Results for 2021 included revenue of $ 5,955 and net income of $ 440 from IriSys. The following table presents unaudited supplemental pro forma financial information as if the IriSys acquisition had occurred on January 1, 2020: Year ended December 31, 2021 2020 Revenue $ 83,045 $ 78,881 Net income (loss) ( 11,809 ) ( 28,290 ) The pro forma financial information presented above has been prepared by combining the Company’s historical results and the historical results of IriSys and adjusting those results to eliminate historical transaction costs and to reflect the effects of the acquisition as if they occurred on January 1, 2020. The effects of the acquisition on the historical pro forma financial information include additional depreciation and amortization expense from the increase of asset carrying values to fair value, the adoption of new accounting standards, additional interest expense from the issuance of the subordinated promissory note and the elimination of interest expense related to indebtedness of IriSys prior to the acquisition. These results do not purport to be indicative of the results of operations which actually would have resulted had the acquisitions occurred on the date indicated above, or that may result in the future, and do not reflect potential synergies or additional costs following the acquisition.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(16)   Fair value of financial instruments The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments and certain warrants. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Items measured at fair value on a recurring basis Cash equivalents of $ 6,034 at December 31, 2022 and $ 15,247 at December 31, 2021 consisted entirely of money market mutual funds whose fair value were determined using Level 1 measurements. Fair value disclosures The Company follows the disclosure provisions of FASB ASC Topic 825, “ Financial Instruments ” (ASC 825), for disclosure purposes for financial assets and financial liabilities that are not measured at fair value. As of December 31, 2022, the financial assets and liabilities recorded on the consolidated balance sheets that are not measured at fair value on a recurring basis include accounts receivable, accounts payable and accrued expenses. The carrying values of these financial assets and liabilities approximate fair value due to their short-term nature. The fair value of long-term debt, where a quoted market price is not available, is evaluated based on, among other factors, interest rates currently available to the Company for debt with similar terms, remaining payments and considerations of the Company’s creditworthiness. The Company determined that the recorded book value of its debt, a level 2 measurement, approximated fair value at December 31, 2022 due to the recent issuances of those instruments and taking into consideration management's current evaluation of market conditions.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Leases	(17)   Leases The Company is party to two operating leases for development facilities in California and Georgia that end in 2031 and 2025 , respectively, as well as other immaterial operating leases for office space, storage and office equipment. The development facility leases each include options to extend, none of which are included in the lease terms. Short-term and variable lease costs were not material for the periods presented. The development facility leases do not provide an implicit rate, so the Company uses its incremental borrowing rate to discount the lease liabilities. Undiscounted future lease payments for the two development leases, which were the only material noncancelable leases at December 31, 2022, were as follows: Twelve months ended December 31, 2023 $ 1,165 2024 1,193 2025 1,158 2026 1,097 2027 1,127 Thereafter 3,681 Total lease payments 9,421 Less imputed interest ( 3,758 ) Total operating lease liabilities $ 5,663 At December 31, 2022, the weighted average remaining lease term was 7.8 years, and the weighted average discount rate was 14.1 % . Total lease cost was $ 1,980 in 2022, $ 814 in 2021 and $ 310 in 2020 .

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	(18)   Related Party Transaction s The former equity holder of IriSys beneficially owned more than 10 % of the Company’s common stock and became a related party on August 13, 2021 as a result of the acquisition of IriSys (see notes 10 and 15). In December 2022, it ceased to meet the definition of a related party following the issuance of additional common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Principles (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The Company’s consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. The Company has determined that it operates in a single segment. Reclassification The Company reclassified certain prior year amounts on the consolidated balance sheet to conform to the current year presentation. These reclassifications had no impact on the previously reported total assets, liabilities or shareholders’ equity.
Reclassification	Reclassification The Company reclassified certain prior year amounts on the consolidated balance sheet to conform to the current year presentation. These reclassifications had no impact on the previously reported total assets, liabilities or shareholders’ equity.
Use of estimates	Use of estimates The preparation of financial statements and the notes to the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.
Business combinations	Business combinations The Company measures the purchase price paid for acquired companies based on fair value and allocates that purchase price to the assets acquired and liabilities assumed based on their estimated fair values. Valuations are performed to assist in determining the fair values of assets acquired and liabilities assumed, which requires management to make estimates and assumptions, in particular with respect to intangible assets. Management makes estimates of fair value based upon assumptions believed to be reasonable. These estimates are based in part on historical experience and information obtained from the acquired companies and expectations of future cash flows. Costs associated with business combinations are expensed as incurred as selling, general and administrative expenses.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents represent cash in banks and highly liquid short-term investments that have maturities of three months or less when acquired. These highly liquid short-term investments are both readily convertible to known amounts of cash and so near to their maturity that they present insignificant risk of changes in value due to changes in interest rates.
Accounts receivable, net	Accounts receivable, net Accounts receivable generally represent amounts billed for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for credit losses, if necessary. We apply judgment in assessing the ultimate realization of our receivables, and we estimate an allowance for credit losses based on various factors, such as the aging of our receivables, historical experience, and the financial condition of our customers. The allowance for credit losses was not material as of the balance sheet dates presented.
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value. Included in inventory are raw materials and work-in-process used in the production of commercial products. Items are issued out of inventory using the first-in, first-out method. Adjustments to inventory are determined at the raw materials, work-in-process, and finished good levels to reflect obsolescence or impaired balances. Factors influencing inventory obsolescence include changes in demand, product life cycle, product pricing, physical deterioration and quality concerns.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, which are as follows: three to ten years for furniture, office and computer equipment; six to ten years for manufacturing equipment; 40 years for buildings; and the shorter of the lease term or useful life for leasehold improvements. Repairs and maintenance costs are expensed as incurred. The Company reviews the carrying value of property, plant and equipment for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of individual assets or asset groups may not be recoverable. The Company considers assets to be held for sale when (i) management commits to a plan to sell the asset; (ii) the asset is available for immediate sale in its present condition; (iii) the asset is actively being marketed for sale at a price that is reasonable given the estimate of current market value; and (iv) the sale is probable and will be completed within one year. Upon designation of an asset as held for sale, the Company records the asset’s value at the lower of its carrying value plus selling costs or its estimated net realizable value.
Goodwill and intangible assets	Goodwill and intangible assets Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company in a business combination. Goodwill is not amortized but assessed for impairment on an annual basis or more frequently if impairment indicators exist. The impairment analysis for goodwill consists of an optional qualitative assessment potentially followed by a quantitative analysis. If the Company determines that the carrying value of its reporting unit exceeds its fair value, an impairment charge is recorded for the excess. The Company performs its annual goodwill impairment test as of November 30 th , or whenever an event or change in circumstance occurs that would require reassessment of the impairment of goodwill. In performing the evaluation, the Company assesses qualitative factors such as overall financial performance, actual and anticipated changes in industry and market conditions, and competitive environments. As a result of the most recent annual goodwill impairment test, the Company determined that there was no impairment of goodwill. Definite-lived intangible assets are amortized on a straight-line basis over their estimated useful life. The Company is required to review the carrying value of definite-lived intangible assets for recoverability whenever events occur or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable.
Leases	Leases The Company determines under U.S. GAAP if an arrangement is a lease at inception. The arrangement is a lease if it conveys the right to the Company to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Options to extend the lease are included in the lease term if the options are reasonably certain to be exercised. Operating lease expense is recognized on a straight-line basis over the lease term. In a sale-leaseback transaction, the Company determines under U.S. GAAP if the transaction meets the requirements of a sale and purchase. If the Company determines that it did not relinquish control of the assets to the buyer-lessor, it does not qualify for sale-leaseback accounting. Operating lease balances are presented as separate captions on the balance sheets. Finance lease assets are included in property, plant and equipment. Finance lease liabilities are included in other liabilities.
Contingencies	Contingencies The Company’s business exposes it to various contingencies including compliance with regulations, legal exposures and other matters. Loss contingencies are reflected in the financial statements based on management's assessments of their expected outcome or resolution: • They are recognized as liabilities on the balance sheet if the potential loss is probable and the amount can be reasonably estimated. • They are disclosed if the potential loss is material and considered at least reasonably possible. Significant judgment is required to determine probability and whether the amount can be reasonably estimated. Due to uncertainties related to these matters, accruals are based only on the information available at the time. As additional information becomes available, the Company reassesses potential liabilities and may revise previous estimates.
Revenue recognition	Revenue recognition The Company generates revenues from manufacturing, packaging, research and development and related services for multiple pharmaceutical companies. Manufacturing Manufacturing and other related services revenue is recognized upon transfer of control of a product to a customer, generally upon shipment, based on a transaction price that reflects the consideration the Company expects to be entitled to as specified in the agreement with the commercial partner, which could include variable consideration such as pricing and volume-based adjustments. Profit-sharing In addition to manufacturing and packaging revenue, certain customers who use our technologies are subject to agreements that provide us intellectual property sales-based profit-sharing and/or royalties consideration, collectively referred to as profit-sharing, computed on the net product sales of the commercial partner. Profit-sharing revenues are generally recognized under the terms of the applicable license, development and/or supply agreement. The Company has determined that in its arrangements, the license for intellectual property is not the predominant item to which the profit-sharing relates, so the Company recognizes revenue upon transfer of control of the manufactured product. In these cases, significant judgment is required to calculate the estimated variable consideration from such profit-sharing using the expected value method based on historical commercial partner pricing and deductions. Estimated variable consideration is partially constrained due to the uncertainty of price adjustments made by the Company’s commercial partners, which are outside of the Company’s control. Factors causing price adjustments by the Company’s commercial partners include increased competition in the products’ markets, mix of volume between the commercial partners’ customers, and changes in government pricing. Research and development Research and development revenue includes services associated with formulation, process development, clinical trials materials services, as well as custom development of manufacturing processes and analytical methods for a customer’s non-clinical, clinical and commercial products. Such revenues are recognized at a point in time or over time depending on the nature and particular facts and circumstances associated with the contract terms. In contracts that specify milestones, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments related to arrangements under which the Company has continuing performance obligations are deferred and recognized over the period of performance. Milestone payments that are not within the Company’s control, such as submission for approval to regulators by a commercial partner or approvals from regulators, are not considered probable of being achieved until those submissions are submitted by the customer or approvals are received. In contracts that require revenue recognition over time, the Company utilizes input or output methods, depending on the specifics of the contract, that compare the cumulative work-in-process to date to the most current estimates for the entire performance obligation. Under these contracts, the customer typically owns the product details and process, which have no alternative use. These projects are customized to each customer to meet its specifications, and typically only one performance obligation is included. Each project represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by the Company’s services and can make changes to its process or specifications upon request. Contract assets represent revenue recognized for performance obligations completed or in process before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. Contract liabilities represent payments received from customers prior to the completion of associated performance obligations.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. The Company manages its cash and cash equivalents based on established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company’s accounts receivable balances are primarily concentrated among two customers with balances of 64 %. If any of these customers’ receivable balances should be deemed uncollectible, it could have a material adverse effect on the Company’s results of operations and financial condition. The Company is dependent on its relationships with a small number of commercial partners. The Company’s four largest customers generated 77 % of revenues in 2022 while the Company’s three largest customers generated 82 % of revenues in 2021 .
Stock-based compensation expense	Stock-based compensation expense The Company measures employee stock-based awards at grant-date fair value and recognizes employee compensation expense on a straight-line basis over the vesting period of the award. The Company accounts for forfeitures as they occur. Determining the appropriate fair value of stock options requires the use of subjective assumptions, including the expected life of the option and expected stock price volatility. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and/or management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options was estimated using the “simplified method,” which is based on the average of the vesting tranches and the contractual life of each grant. For stock price volatility, the Company uses the historical volatility of its publicly traded stock in order to estimate future stock price trends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. Upon exercise of stock options or vesting of restricted stock units, the holder may elect to cover tax withholdings by forfeiting shares of an equivalent value. In such cases, the Company issues net new shares to the holder, pays the tax withholding on behalf of the participant and presents the payment similar to a capital distribution: a reduction to additional paid-in-capital and a financing cash outflow in the consolidated financial statements.
Income taxes	Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, operating losses and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. In assessing the realizability of net deferred tax assets, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. A full valuation allowance was recorded as of December 31, 2022 and December 31, 2021. Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the consolidated financial statements. The Company recognizes the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company does not anticipate significant changes in the amount of unrecognized income tax benefits over the next year.
Income or loss per share	Income or loss per share Net loss per common share is computed using the two-class method required due to the participating nature of the Series A Convertible Preferred Stock (as defined and discussed in note 10) given the rights to participate in dividends if declared on common stock. The two-class method is an earnings allocation formula that treats participating securities as having rights to earnings that would otherwise have been available to common stockholders. In addition, as these securities are participating securities, the Company is required to calculate diluted net income or loss per share under the if-converted and treasury stock method in addition to the two-class method and utilize the most dilutive result. In periods where there is a net loss, no allocation of undistributed net loss to the Series A Convertible Preferred stockholders is performed as the holders of these securities are not contractually obligated to participate in the Company’s losses. Basic income or loss per share is determined by dividing net income or loss (the numerator) by the weighted average common shares outstanding during the period (the denominator). Additionally, the weighted average common shares outstanding for the year ended December 31, 2021 include 9,302,718 shares issuable to the former equity holders of IriSys, since the acquisition date. To calculate diluted income or loss per share, the numerator and denominator are adjusted to eliminate the income or loss and the dilutive effects on shares, respectively, caused by outstanding common stock options, warrants and unvested restricted stock units, using the treasury stock method, if the inclusion of such instruments would be dilutive. For all years presented, the Company incurred a net loss. In periods of net loss, the inclusion of dilutive securities would be antidilutive because it would reduce the amount of loss incurred per share. As a result, no additional dilutive shares were included in diluted loss per share, and there were no differences between basic and diluted loss per share. The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share: Year ended December 31, 2022 2021 2020 Restricted stock units 1,583,469 731,525 684,852 Stock options 7,317,274 4,645,109 3,577,605 Warrants 362,030 348,664 348,664 Amounts in the table above reflect the common stock equivalents of the noted instruments.
Fair Value Measurement	The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ,” for fair value measurement recognition and disclosure purposes for its financial assets and financial liabilities that are remeasured and reported at fair value each reporting period. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, short-term investments and certain warrants. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of financial assets and financial liabilities and their placement within the fair value hierarchy. Categorization is based on a three-tier valuation hierarchy, which prioritizes the inputs used in measuring fair value, as follows: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level 2: Inputs that are other than quoted prices in active markets for identical assets and liabilities, inputs that are quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are either directly or indirectly observable; and • Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Summary of Significant Accoun_3

Summary of Significant Accounting Principles (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Anti-Dilutive Securities	The following table presents the potentially dilutive securities that were excluded from the computations of diluted loss per share: Year ended December 31, 2022 2021 2020 Restricted stock units 1,583,469 731,525 684,852 Stock options 7,317,274 4,645,109 3,577,605 Warrants 362,030 348,664 348,664

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Components of Inventory	The following table presents the components of inventory: December 31, 2022 December 31, 2021 Raw materials $ 4,318 $ 3,038 Work in process 3,689 3,363 Finished goods 2,294 2,516 Inventory $ 10,301 $ 8,917

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Rollforward Goodwill	The following table presents the rollforward of goodwill: Balance, December 31, 2020 $ 4,319 Acquisition of IriSys 36,758 Balance, December 31, 2021 and 2022 $ 41,077
Summary of Components of Other Intangible Assets	The following table presents the components of other intangible assets: December 31, 2022 December 31, 2021 Gross value Accumulated amortization Carrying value Gross value Accumulated amortization Carrying value Customer relationships $ 18,900 $ 16,188 $ 2,712 $ 18,900 $ 15,685 $ 3,215 Backlog 460 261 199 460 73 387 Trademarks and tradenames 310 293 17 310 79 231 Total $ 19,670 $ 16,742 $ 2,928 $ 19,670 $ 15,837 $ 3,833
Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense	The following table presents estimated future amortization of other intangible assets: Twelve months ending December 31, 2023 $ 687 2024 501 2025 486 2026 486 2027 486 Thereafter 282 Total $ 2,928

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	: December 31, 2022 December 31, 2021 Land $ 604 $ 3,263 Building and improvements 22,751 22,717 Furniture, office and computer equipment 6,388 6,213 Manufacturing equipment 58,039 49,687 Construction in process 7,024 6,856 Property, plant and equipment, gross 94,806 88,736 Less: accumulated depreciation ( 44,441 ) ( 37,028 ) Property, plant and equipment, net $ 50,365 $ 51,708

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: December 31, 2022 December 31, 2021 Payroll and related costs $ 4,276 $ 5,717 Accrued transaction costs 3,653 — Contract liabilities (see note 11) 2,211 2,308 Property, plant and equipment 934 663 Professional and consulting fees 356 552 Accrued interest 227 2,505 Other 1,029 811 Total $ 12,686 $ 12,556

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Components and Classification of Debt	The following table presents the components and classification of debt: December 31, 2022 December 31, 2021 Debt principal: Term loan under Credit Agreement $ 36,900 $ — Term loans with Athyrium — 100,000 Note with former equity holder of IriSys 4,078 6,117 Other 339 339 Debt principal 41,317 106,456 Debt adjustments: Unamortized deferred issuance costs ( 2,476 ) — Unamortized deferred issuance costs with Athyrium — ( 8,896 ) Exit fee accretion — 669 Unamortized original discount ( 297 ) ( 694 ) Carrying value of debt $ 38,544 $ 97,535 Current portion of debt $ 7,577 $ 2,039 Debt, net of current portion 30,967 95,496 Carrying value of debt $ 38,544 $ 97,535
Schedule of Future Maturities of Debt	The following table presents the future maturity of debt principal: Twelve months ending December 31, 2023 $ 7,577 2024 4,823 2025 28,626 2026 39 2027 46 Thereafter 206 Total debt principal $ 41,317

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Changes in Contract Assets and Liabilities	The following table presents changes in contract assets and liabilities: Contract assets Contract liabilities Balance at December 31, 2021 $ 8,565 $ ( 2,308 ) Changes to the beginning balance arising from: Reclassification to receivables as the result of rights to consideration becoming unconditional ( 11,298 ) — Reclassification to revenue as the result of performance obligations satisfied 1,078 2,022 Changes in estimate 1,869 17 Net change to contract balance recognized since beginning of period due to recognition of revenue, amounts billed and changes in estimate 8,510 ( 1,942 ) Balance at December 31, 2022 $ 8,724 $ ( 2,211 ) Contract assets and contract liabilities are reported at the contract level. Contracts with multiple performance obligation are reported as a net contract asset or contract liability on the consolidated balance sheet. The reclassification to revenue appearing in the contract assets column results from the recognition of revenue on contract liabilities that are presented as a net contract asset at the beginning of the year
Disaggregation of Revenue by Timing of Revenue Recognition	The following table disaggregates revenue by timing of revenue recognition: Year ended December 31, 2022 2021 2020 Point in time $ 70,325 $ 60,992 $ 61,616 Over time 19,889 14,368 4,883 Total $ 90,214 $ 75,360 $ 66,499

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Fair Value of Stock Options Granted	The following table presents information about the fair value of stock options granted: Year ended December 31, 2022 2021 2020 Weighted average grant date fair value $ 1.02 $ 1.77 $ 5.14 Assumptions used to determine fair value: Range of expected option life 5.5 - 6.0 years 5.5 - 6.0 years 5.5 - 6.0 years Expected volatility 79 - 81 % 79 - 81 % 75 - 81 % Risk-free interest rate 1.5 - 4.0 % 0.7 - 1.4 % 0.3 - 1.4 % Expected dividend yield — — —
Summary of Stock Option Activity	The following table presents information about stock option balances and activity: Number of shares Weighted average exercise price Aggregate intrinsic value Weighted average remaining contractual life Balance, December 31, 2021 5,267,567 $ 6.47 5.7 years Granted 4,055,633 1.49 Exercised ( 516 ) 1.32 Exchanged ( 668,009 ) 9.79 Forfeited or expired ( 604,338 ) 3.75 Balance, December 31, 2022 8,050,337 3.89 $ — 6.6 years Exercisable 4,054,697 6.01 — 4.4 years
Summary of Restricted Stock Units Activity	The following table presents information about recent RSU activity: Number of shares Weighted average grant date fair value Balance, December 31, 2021 990,065 $ 3.63 Granted 1,552,590 1.32 Exchanged 167,094 0.80 Vested ( 587,895 ) 3.56 Forfeited ( 59,988 ) 2.44 Balance, December 31, 2022 2,061,866 1.71
Summary of Stock Based Compensation Expense	The following table presents the classification of stock-based compensation expense: Year ended December 31, 2022 2021 2020 Cost of sales $ 1,868 $ 2,797 $ 3,754 Selling, general and administrative expenses 3,558 3,717 6,314 Total $ 5,426 $ 6,514 $ 10,068

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Components of Income Tax Provision (Benefit) From Continuing Operations	All of the Company’s income from continuing operations is domestic. The components of the income tax provision from continuing operations are as follows: Year ended December 31, 2022 2021 2020 Current: Federal $ 33 $ — $ — State 57 — — Total current 90 — — Deferred: Federal 1,399 ( 2,396 ) ( 5,539 ) State 4,266 ( 677 ) ( 1,596 ) Total deferred 5,665 ( 3,073 ) ( 7,135 ) Change in valuation allowance ( 4,650 ) 3,073 7,135 Income tax expense $ 1,105 $ — $ —
Reconciliation of Statutory U.S. Federal Income Tax Rate to Effective Tax Rate From Continuing Operations	A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate is as follows: Year ended December 31, 2022 2021 2020 U.S. federal statutory income tax rate 21 % 21 % 21 % State taxes, net of federal benefit 7 % 8 % 6 % Change in state tax rate ( 22 )% ( 2 )% — Nondeductible expenses ( 5 )% ( 1 )% ( 1 )% Research and development credits ( 23 )% 1 % — Change in valuation allowance 16 % ( 27 )% ( 26 )% Other — — — Effective income tax rate ( 6 )% — —
Schedule of Tax Effects of Temporary Differences to Significant Portions of Deferred Tax Assets	The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 33,352 $ 38,970 Interest expense 12,944 13,960 Sale-leaseback 9,093 — Stock-based compensation 4,681 4,459 Research and development credits — 4,581 Other 3,950 4,635 Gross deferred tax asset 64,020 66,605 Valuation allowance ( 50,909 ) ( 55,421 ) Deferred tax assets, net of valuation allowance 13,111 11,184 Deferred tax liabilities: Depreciation ( 10,750 ) ( 7,057 ) Contract assets ( 2,082 ) ( 2,346 ) Other ( 1,294 ) ( 1,781 ) Deferred tax liabilities ( 14,126 ) ( 11,184 ) Net deferred tax liabilities $ ( 1,015 ) $ —
Summary of Carryforward of Net Operating Losses	The following table summarizes carryforwards of net operating losses as of December 31, 2022: Amount Expiration Federal net operating losses, 2008 to 2017 $ 76 2028 Federal net operating losses, 2018 to 2022 125,501 No expiration State net operating losses 135,420 2028 – 2042

Acquisition of IriSys (Tables)

Acquisition of IriSys (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Schedule of Business Acquisition of Purchase Price Consideration	The following table summarizes the consideration paid: August 13, 2021 Cash paid, net of cash acquired $ 24,002 Net working capital adjustment receivable ( 417 ) Fair value of shares issuable to former equity holders of IriSys 20,931 Fair value of note with former equity holder of IriSys 5,240 Total estimated consideration $ 49,756
Schedule of Fair Values of the Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition: As of August 13, 2021 Assets acquired: Accounts receivable $ 909 Contract assets 505 Inventory 685 Prepaid expenses and other current assets 91 Property and equipment 9,304 Operating lease asset 5,648 Intangible assets 4,170 Goodwill 36,758 Other assets 146 Total assets acquired $ 58,216 Liabilities assumed: Accounts payable $ 730 Accrued expenses and other current liabilities 1,556 Operating lease liability 5,648 Debt from finance loan 339 Other liabilities 187 Total liabilities assumed $ 8,460 Net assets acquired $ 49,756
Schedule of Intangible Assets Acquired	The following table presents information about the acquired identifiable intangible assets: Fair value Weighted average amortization period Customer relationships $ 3,400 7.0 years Backlog 460 2.4 years Trademarks and tradenames 310 1.5 years Total $ 4,170 6.1 years
Schedule of Supplemental Pro Forma Financial Information	The following table presents unaudited supplemental pro forma financial information as if the IriSys acquisition had occurred on January 1, 2020: Year ended December 31, 2021 2020 Revenue $ 83,045 $ 78,881 Net income (loss) ( 11,809 ) ( 28,290 )

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Schedule of Undiscounted Future Lease Payments for the Development Lease	Undiscounted future lease payments for the two development leases, which were the only material noncancelable leases at December 31, 2022, were as follows: Twelve months ended December 31, 2023 $ 1,165 2024 1,193 2025 1,158 2026 1,097 2027 1,127 Thereafter 3,681 Total lease payments 9,421 Less imputed interest ( 3,758 ) Total operating lease liabilities $ 5,663

Background - Additional Informa

Background - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation date	Nov. 15, 2007
Accumulated deficit	$ 265,635	$ 245,754

Summary of Significant Accoun_4

Summary of Significant Accounting Principles - Additional Information (Detail)		12 Months Ended
	Aug. 13, 2021 shares	Dec. 31, 2022 Customer	Dec. 31, 2021 shares
Accounts Receivable [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of customers | Customer		2
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Cash [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage		64%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Cash [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Concentration risk percentage		77%	82%
Furniture and Office Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		3 years
Furniture and Office Equipment [Member] | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		10 years
Manufacturing Equipment [Member] | Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		6 years
Manufacturing Equipment [Member] | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		10 years
Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment estimated useful lives		40 years
Leasehold Improvements [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Property, plant and equipment useful life		the shorter of the lease term or useful life
Irisys LLC [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of share issued for acquisition | shares	9,302,718		9,302,718

Summary of Significant Accoun_5

Summary of Significant Accounting Principles - Schedule of Anti-Dilutive Securities (Detail) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	1,583,469	731,525	684,852
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	7,317,274	4,645,109	3,577,605
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	362,030	348,664	348,664

Inventory - Components of Inven

Inventory - Components of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 4,318	$ 3,038
Work in process	3,689	3,363
Finished goods	2,294	2,516
Inventory	$ 10,301	$ 8,917

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Rollforward Goodwill (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 4,319
Acquisition of IriSys	36,758
Goodwill, Ending Balance	$ 41,077

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Summary of Components of Other Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross value	$ 19,670	$ 19,670
Accumulated amortization	16,742	15,837
Carrying value	2,928	3,833
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross value	18,900	18,900
Accumulated amortization	16,188	15,685
Carrying value	2,712	3,215
Backlog [Member]
Finite-Lived Intangible Assets [Line Items]
Gross value	460	460
Accumulated amortization	261	73
Carrying value	199	387
Trademarks and Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Gross value	310	310
Accumulated amortization	293	79
Carrying value	$ 17	$ 231

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 687
2024	501
2025	486
2026	486
2027	486
Thereafter	282
Carrying value	$ 2,928	$ 3,833

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 94,806	$ 88,736
Less: accumulated depreciation	(44,441)	(37,028)
Property, plant and equipment, net	50,365	51,708
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	604	3,263
Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	22,751	22,717
Furniture, Office & Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	6,388	6,213
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	58,039	49,687
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 7,024	$ 6,856

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2022 a
Property, Plant and Equipment [Line Items]
Interest Expense	$ 14,059	$ 15,134	$ 19,159
Sale lease back transaction description of assets	In December 2022, the Company concurrently entered into sale and lease agreements with Tenet Equity Funding SPE Gainesville, LLC (“Tenet”) related to its commercial manufacturing campus in Gainesville, Georgia. The selling price was $39,000, of which $1,750 was retained by Tenet as a lease deposit and classified within other assets, resulting in cash proceeds to the Company of $37,250 in 2022. The lease is for an initial term of 20 years with four renewal options of ten years each. Rent under the lease will be payable monthly at a rate of $3,510 per year, increasing annually by 3%, except for the first year where annual base rent will increase by the change in the consumer price index, not to exceed 5%, if greater. The Company is responsible for the payment of all operating expenses, property taxes and insurance for the property. Pursuant to the terms of the lease, the Company will have a purchase option every ten years and a right of first offer and a right of first refusal to purchase the property should the buyer-lessor intend to sell the property to a third party.
Sale lease back transaction date	December 2022
Lease initial term	20 years
Gainesville, Georgia [Member]
Property, Plant and Equipment [Line Items]
Purchase price	$ 39,000
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Interest Expense	1,195	$ 424
Land [Member]
Property, Plant and Equipment [Line Items]
Area Of Land | a				121
Proceeds from Sale of property plant and equipment	9,075
Carrying value of other assets	$ 2,659

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Payroll and related costs	$ 4,276	$ 5,717
Accrued transaction costs	3,653	0
Contract liabilities (see note 11)	2,211	2,308
Property, plant and equipment	934	663
Professional and consulting fees	356	552
Accrued interest	227	2,505
Other	1,029	811
Total	$ 12,686	$ 12,556

Accrued expenses and other cu_4

Accrued expenses and other current liabilities - Additional Information (Detail) - Term Loan Under Credit Agreement [Member] $ in Thousands	Dec. 31, 2022 USD ($)
Borrowing amount	$ 36,900
Gainesville, Georgia [Member]
Borrowing amount	$ 36,900

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Executive Officer [Member]
Supply Commitment [Line Items]
Potential severance commitments arrangement consideration	$ 1,303
Other Contingencies	3,772
Purchase Commitment [Member]
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable	$ 9,732

Debt - Components and Classific

Debt - Components and Classification of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt principal	$ 41,317	$ 106,456
Unamortized deferred issuance costs	(2,476)	0
Exit fee accretion	0	669
Unamortized original discount	(297)	(694)
Carrying value of debt	38,544	97,535
Current portion of debt	7,577	2,039
Debt, net of current portion	30,967	95,496
Athyrium Opportunities II Acquisition LP [Member]
Debt Instrument [Line Items]
Debt principal	0	100,000
Unamortized deferred issuance costs	0	(8,896)
Term Loan Under Credit Agreement [Member]
Debt Instrument [Line Items]
Debt principal	36,900	0
Current portion of debt	3,693
Note with Former [Member]
Debt Instrument [Line Items]
Debt principal	4,078	6,117
Other [Member]
Debt Instrument [Line Items]
Debt principal	$ 339	$ 339

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2023	$ 7,577
2024	4,823
2025	28,626
2026	39
2027	46
Thereafter	206
Total debt principal	$ 41,317	$ 106,456

Debt - Additional Information (

Debt - Additional Information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
	May 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Debt Instrument [Line Items]
Long term debt, maturity, year one		$ 7,577
Long term debt, maturity, year two		4,823
Long term debt, maturity, year three		28,626
Cash and cash equivalents		14,995	$ 25,217
Carrying value of debt		38,544	97,535
Debt instrument, exit fee		0	669
Non-cash interest expense		4,845	5,815	$ 5,510
Current portion of debt		7,577	2,039
Debt principal		41,317	106,456
Gain on extinguishment of debt		(4,996)	3,352	0
Athyrium Opportunities II Acquisition LP [Member]
Debt Instrument [Line Items]
Debt principal		$ 0	100,000
Athyrium Opportunities I I I Acquisition Limited Partnership Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Dec. 31, 2023
Credit agreement			100,000
Term loan interest rate, description		an interest rate equal to the three-month LIBOR rate, with a 1% floor plus 8.25% per annum
Non-cash interest expense		$ 4,411	5,558	$ 5,510
Gain on extinguishment of debt		$ 4,996
Athyrium Opportunities I I I Acquisition Limited Partnership Credit Agreement [Member] | Floor [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		1%
Athyrium Opportunities I I I Acquisition Limited Partnership Credit Agreement [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		8.25%
Athyrium Second Amendment Credit Agreement [Member]
Debt Instrument [Line Items]
Effective interest rate		16.40%
Note With Former Member of IriSys [Member]
Debt Instrument [Line Items]
Debt instrument, maturity date		Aug. 13, 2024
Carrying value of debt		$ 6,117
Debt Instrument, Interest Rate, Stated Percentage		6%
Interest paid		$ 367
Long-term debt term		3 years
Accrued Interest		$ 94
Unamortized original discount		$ 877
Debt Instrument, Interest Rate, Basis for Effective Rate		13.0
Others [Member]
Debt Instrument [Line Items]
Debt principal		$ 339
Term Loan Under Credit Agreement [Member]
Debt Instrument [Line Items]
Credit agreement		36,900
Long term debt, maturity, year one		1,845
Long term debt, maturity, year two		2,768
Long term debt, maturity, year three		$ 3,690
Repayment Terms		The outstanding principal amount will be repaid in equal quarterly payments totaling $1,845 in 2023, $2,768 in 2024 and $3,690 in 2025, with the remaining principal balance due December 16, 2025. If the Company completes a sale of certain real property by December 14, 2023 and makes the $10,000 principal repayment disclosed below, the quarterly principal payments will be reduced proportionately to the reduction in principal
Repayment of debt within 12 months of credit agreement closing upon the sale of real property		$ 10,000
Cash and cash equivalents		4,000
Cash and cash equivalents to be maintained over time		$ 5,000
Minimum fixed charge ratio		1.15
Term loan interest rate, description		interest at a floating rate equal to the three-month term Secured Overnight Financing Rate, or SOFR, with an initial floor of 1.00%, plus an applicable margin that is equal to 4.50% per annum for the first year, 5.00% for the second year and 5.50% for the third year, with quarterly interest payments due until maturity
Debt instrument, early repayment terms		Subject to certain exceptions, the Company is required to make mandatory prepayments with the cash proceeds received in respect of asset sales, extraordinary receipts and debt issuances, upon a change of control and specified other events. Additionally, the Company is obligated to repay $10,000 of principal by December 14, 2023 upon the sale of certain real property adjacent to its Gainesville, Georgia manufacturing campus (see note 5). If that property is not sold by December 14, 2023, the Company will be required to pay a fee of $369 and increase each of its quarterly principal payments by $231 until that property is sold and the $10,000 principal payment is made. Because the Company concluded that the sale of the property is probable as of December 31, 2022, an additional $3,693 of debt principal has been presented as current, representing the carrying value of the current asset held for sale plus the $925 excess of the principal payment over the expected proceeds from the asset
Fee on debt instrument		369
Increase in qauterly repayments		$ 231
Excess payment of debt over principal payments		$ 925
Effective interest rate		11.70%
Non-cash interest expense		$ 35
Current portion of debt		3,693
Debt principal		$ 36,900	0
Term Loan Under Credit Agreement [Member] | Maximum
Debt Instrument [Line Items]
Maximum leverage ratio		3.75
Term Loan Under Credit Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Maximum leverage ratio		2.75
Term Loan Under Credit Agreement [Member] | First Year [Member] | Floor [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		1%
Term Loan Under Credit Agreement [Member] | First Year [Member] | SOFR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		4.50%
Term Loan Under Credit Agreement [Member] | Second Year [Member] | SOFR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		5%
Term Loan Under Credit Agreement [Member] | Third Year [Member] | SOFR [Member]
Debt Instrument [Line Items]
Term loan variable interest rate		5.50%
Federal COVID 19 Relief Program [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 4,416
Debt Instrument, Interest Rate, Stated Percentage	1%
Long-term debt term	2 years
Repayments of Long-term Debt	$ 1,100
Gain on extinguishment of debt			3,352
Debt forgiveness			3,316
Accrued interest			$ 36

Other Liabilities - Additional

Other Liabilities - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accelerated Share Repurchases [Line Items]
Sale leaseback liability	$ 38,168
Other liabilities	$ 39,225	$ 90
Sale lease back transaction description of assets	In December 2022, the Company concurrently entered into sale and lease agreements with Tenet Equity Funding SPE Gainesville, LLC (“Tenet”) related to its commercial manufacturing campus in Gainesville, Georgia. The selling price was $39,000, of which $1,750 was retained by Tenet as a lease deposit and classified within other assets, resulting in cash proceeds to the Company of $37,250 in 2022. The lease is for an initial term of 20 years with four renewal options of ten years each. Rent under the lease will be payable monthly at a rate of $3,510 per year, increasing annually by 3%, except for the first year where annual base rent will increase by the change in the consumer price index, not to exceed 5%, if greater. The Company is responsible for the payment of all operating expenses, property taxes and insurance for the property. Pursuant to the terms of the lease, the Company will have a purchase option every ten years and a right of first offer and a right of first refusal to purchase the property should the buyer-lessor intend to sell the property to a third party.
Sale lease back transaction date	December 2022
Lease deposit	$ 1,750
Proceeds from sale-leaseback liability	$ 37,250	$ 0	$ 0
Lease initial term	20 years
Lessee, lease, description	The lease is for an initial term of 20 years with four renewal options of ten years each. Rent under the lease will be payable monthly at a rate of $3,510 per year, increasing annually by 3%, except for the first year where annual base rent will increase by the change in the consumer price index, not to exceed 5%, if greater.
Lessee, lease, renewal term	10 years
Annual base rent under the lease	$ 3,510
Percentage of increase in rent amount	3%
Company recognized liability	$ 38,168
Deferred finance costs net	$ 869
Imputed rate of interest	10.95%
Term of contract under recognize interest expense	20 years
Description of sale leaseback liability, gross liability period	The gross liability balance will increase through 2034, at which point it will decrease through the end of lease term on December 31, 2042.
Maximum
Accelerated Share Repurchases [Line Items]
Percentage of increase in rent amount	5%
Gainesville, Georgia
Accelerated Share Repurchases [Line Items]
Other liabilities	$ 1,057
Selling price	$ 39,000

Shareholders' equity or defic_2

Shareholders' equity or deficit - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Capitalization Equity [Line Items]
Shares of convertible preferred stock issued	450,000	0
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares outstanding	450,000	0
Preferred stock convertible conversion percentage increase	10%
Preferred Class A [Member]
Schedule Of Capitalization Equity [Line Items]
Shares of convertible preferred stock issued	450,000
Convertible preferred stock, par value	$ 11
Warrants, Exercise Price $6.84, Expiring on November 2024 [Member] | Equity [Member] | Athyrium Opportunities II Acquisition LP [Member]
Schedule Of Capitalization Equity [Line Items]
Warrants outstanding to purchase shares, Number of Shares	402,126
Warrant, exercise price per share	$ 1.50
Warrants outstanding to purchase shares, Expiration dates	2024-11

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Changes in Contract Assets and Liabilities (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Contract with Customer Asset
Balance at December 31, 2021	$ 8,565
Changes to the beginning balance of contract assets arising from:
Reclassification to receivables as the result of rights to consideration becoming unconditional	(11,298)
Reclassification to revenue as the result of performance obligations satisfied	1,078
Changes in estimate	1,869
Net change to contract balance recognized since beginning of period due to recognition of revenue, amounts billed and changes in estimate	8,510
Balance at December 31, 2022	8,724
Contract with Customer, Liability
Balance at December 31, 2021	(2,308)
Changes to the beginning balance of contract liabilities arising from :
Reclassification to revenue as the result of performance obligations satisfied	2,022
Changes in estimate	17
Net change to contract balance recognized since beginning of period due to recognition of revenue, amounts billed and changes in estimate	(1,942)
Balance at December 31, 2022	$ (2,211)

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue by Timing of Revenue Recognition (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Revenue	$ 90,214	$ 75,360	$ 66,499
Point In Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	70,325	60,992	61,616
Over Time [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 19,889	$ 14,368	$ 4,883

Retirement Plan - Additional In

Retirement Plan - Additional Information (Detail) - 401(k) Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan, employer matching contribution, percent of match	100%
Defined contribution plan, maximum annual contributions per employee, percent	5%
Contributions by employer	$ 1,348	$ 915	$ 941
Defined contribution plan, description	The Company has a voluntary 401(k) savings plan in which all employees are eligible to participate. The Company’s policy is to match 100% of the employee contributions up to a maximum of 5% of employee compensation. Total Company contributions to the 401(k) plan were $1,348 for 2022, $915 for 2021 and $941 for 2020

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 USD ($) Installments $ / shares shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($) $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options exercisable period		10 years
Stock options vest period		4 years
Weighted average grant date fair value | $ / shares		$ 1.02	$ 1.77	$ 5.14
Intrinsic value of options exercised | $				$ 1,058
Unrecognized compensation expense related to unvested options and time-based RSUs, expected to vest | $	$ 7,108	$ 7,108
Number of annual installment | Installments		2
Unrecognized compensation expense related to unvested options, weighted average period		2 years 1 month 6 days
Share based compensation Number of shares cancelled		668,009
Stock Options Granted Outside Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options, Granted		1,210,552
Number of shares. Granted		77,256
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value | $ / shares		$ 1.32	$ 3.49	$ 5.34
Number of options, Granted		167,094
Number of shares. Granted		1,552,590
Share based compensation Number of shares cancelled		59,988
Fair value vested | $		$ 897	$ 2,663	$ 4,039
Restricted Stock Units [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vest period		6 months
Restricted Stock Units [Member] | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options vest period		4 years
A&R Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of outstanding common stock	5%
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grants	3,237,642	3,237,642

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value of Stock Options Granted (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value	$ 1.02	$ 1.77	$ 5.14
Assumptions used to determine fair value:
Expected dividend yield	0%	0%	0%
Minimum [Member]
Assumptions used to determine fair value:
Range of expected option life	5 years 6 months	5 years 6 months	5 years 6 months
Expected volatility	79%	79%	75%
Risk-free interest rate	1.50%	0.70%	0.30%
Maximum
Assumptions used to determine fair value:
Range of expected option life	6 years	6 years	6 years
Expected volatility	81%	81%	81%
Risk-free interest rate	4%	1.40%	1.40%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of shares, Beginning balance	5,267,567
Number of shares, Granted	4,055,633
Number of shares, Exercised	(516)
Number of shares, Exchanged	(668,009)
Number of shares, Forfeited or expired	(604,338)
Number of shares, Ending balance	8,050,337	5,267,567
Number of shares, Exercisable	4,054,697
Weighted average exercise price, Beginning balance	$ 6.47
Weighted average exercise price, Granted	1.49
Weighted average exercise price, Exercised	1.32
Weighted average exercise price, Exchanged	9.79
Weighted average exercise price, Forfeited or expired	3.75
Weighted average exercise price, Ending balance	3.89	$ 6.47
Weighted average exercise price, Exercisable	$ 6.01
Aggregate intrinsic value	$ 0
Aggregate intrinsic value, Exercisable	$ 0
Weighted average remaining contractual life	6 years 7 months 6 days	5 years 8 months 12 days
Weighted average remaining contractual life, Exercisable	4 years 4 months 24 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Forfeited	(668,009)
Weighted average grant date fair value, Granted	$ 1.02	$ 1.77	$ 5.14
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Beginning balance	990,065
Number of shares. Granted	1,552,590
Number of shares, Exchanged	167,094
Number of shares, Vested	(587,895)
Number of shares, Forfeited	(59,988)
Number of shares, Ending balance	2,061,866	990,065
Weighted average grant date fair value, Beginning balance	$ 3.63
Weighted average grant date fair value, Granted	1.32	$ 3.49	$ 5.34
Weighted average grant date fair value, Exchanged	0.80
Weighted average grant date fair value, Vested	3.56
Weighted average grant date fair value, Forfeited	2.44
Weighted average grant date fair value, Ending balance	$ 1.71	$ 3.63

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock Based Compensation Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 5,426	$ 6,514	$ 10,068
Cost of Sales [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,868	2,797	3,754
Selling General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 3,558	$ 3,717	$ 6,314

Income Taxes - Components of In

Income Taxes - Components of Income Tax Provision (Benefit) From Continuing Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal	$ 33
State	57
Total current	90
Deferred:
Federal	1,399	$ (2,396)	$ (5,539)
State and local	4,266	(677)	(1,596)
Total deferred	5,665	(3,073)	(7,135)
Change in valuation allowance	(4,650)	3,073	7,135
Income tax expense	$ 1,105	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory U.S. Federal Income Tax Rate to Effective Tax Rate From Continuing Operations (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. federal statutory income tax rate	21%	21%	21%
State taxes, net of federal benefit	7%	8%	6%
Change in state tax rate	(22.00%)	(2.00%)	0%
Nondeductible expenses	(5.00%)	(1.00%)	(1.00%)
Research and development credits	23%	1%	0%
Change in valuation allowance	(16.00%)	(27.00%)	(26.00%)
Other	0%	0%	0%
Effective income tax rate	6%	0%	0%

Income Taxes - Schedule of Tax

Income Taxes - Schedule of Tax Effects of Temporary Differences to Significant Portions of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 33,352	$ 38,970
Interest expense	12,944	13,960
Sale leaseback	9,093	0
Stock-based compensation	4,681	4,459
Research and development credits	0	4,581
Other	3,950	4,635
Gross deferred tax asset	64,020	66,605
Valuation allowance	(50,909)	(55,421)
Deferred tax assets, net of valuation allowance	13,111	11,184
Depreciation	(10,750)	(7,057)
Contract assets	(2,082)	2,346
Other	(1,294)	(1,781)
Deferred tax liabilities	(14,126)	(11,184)
Net deferred tax liabilities	$ 1,015	$ 0

Income Taxes - Summary of Carry

Income Taxes - Summary of Carryforward of Net Operating Losses (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Operating Loss Carryforwards [Line Items]
Net operating losses, Expiration period	State net operating loss carryforwards may be further limited, including in Pennsylvania, which has a limitation of 40% of taxable income after modifications and apportionment on state net operating losses utilized in any one year.
Federal [Member] | Tax Year2008 To2017
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 76
Net operating losses, Expiration period start	2028
Federal [Member] | Tax Year 2018 to 2021
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 125,501
Net operating losses, Expiration period	No expiration
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 135,420
Net operating losses, Expiration period start	2028
Net operating losses, Expiration period end	2042

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Line Items]
Operating loss and research and development tax credit carryforwards percentage of change in ownership	50%
Operating loss and research and development tax credit carryforwards percentage of change in ownership period	3 years
Taxable gain on sale for federal and state income tax purposes	$ 25,350
Percentage of limitation on taxable income after modification and apportionment	40%
Net operating loss carryforwards, limitation	State net operating loss carryforwards may be further limited, including in Pennsylvania, which has a limitation of 40% of taxable income after modifications and apportionment on state net operating losses utilized in any one year.
Accrued interest or penalties related to uncertain tax positions	$ 0
Current tax obligation	47
Recognized amounts of interest or penalties related to uncertain tax positions	$ 0
Income tax examination	Due to net operating loss and tax credit carry forwards that remain unutilized, income tax returns for tax years since inception remain subject to examination by the taxing jurisdictions.
Deferred tax provision	$ 1,015
Reduction in corporate tax rate	(22.00%)	(2.00%)	0%
PENNSYLVANIA
Income Taxes [Line Items]
Reduction in corporate tax rate	4.99%
Income Tax Rate Deduction, Percent	0.50%
Maximum [Member] | PENNSYLVANIA
Income Taxes [Line Items]
Reduction in corporate tax rate	9.90%
Minimum [Member] | PENNSYLVANIA
Income Taxes [Line Items]
Reduction in corporate tax rate	8.90%

Acquisition of IriSys (Addition

Acquisition of IriSys (Additional Information) (Detail) - USD ($) $ in Thousands		12 Months Ended
	Aug. 13, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Indefinite-lived intangible assets fair value		$ 4,170
Net loss		(19,881)	$ (11,370)	$ (27,501)
Customer Relationships [Member]
Business Acquisition [Line Items]
Indefinite-lived intangible assets fair value		$ 3,400
Irisys LLC [Member]
Business Acquisition [Line Items]
Date of acquisition agreement	Aug. 13, 2021
Number of share issued for acquisition	9,302,718		9,302,718
Business acquisition transaction costs	$ 1,211
Revenues			$ 5,955
Net loss			$ 440

Acquisition of IriSys - Schedul

Acquisition of IriSys - Schedule of Business Acquisition of Purchase Price Consideration (Detail) - USD ($) $ in Thousands		12 Months Ended
	Aug. 13, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Cash paid, net of cash acquired		$ 0	$ 24,002	$ 0
Net working capital adjustment receivable	$ (417)
Irisys LLC [Member]
Business Acquisition [Line Items]
Cash paid, net of cash acquired	24,002
Fair value of forward equity issuance	20,931
Fair value of note with former members of IriSys	5,240
Total estimated consideration	$ 49,756

Acquisition of IriSys - Sched_2

Acquisition of IriSys - Schedule of Provisional Fair Values of the Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Aug. 13, 2021
Assets acquired:
Operating lease asset	$ 5,491	$ 5,924
Irisys LLC [Member]
Assets acquired:
Accounts receivable			$ 909
Contract assets			505
Inventory			685
Prepaid expenses and other current assets			91
Property and equipment			9,304
Operating lease asset			5,648
Intangible assets			4,170
Goodwill			36,758
Other assets			146
Total assets acquired			58,216
Liabilities assumed:
Accounts payable			730
Accrued expenses and other current liabilities			1,556
Operating lease liability			5,648
Debt from finance loan			339
Other liabilities			187
Total liabilities assumed			8,460
Net assets acquired			$ 49,756

Acquisition of IriSys - Sched_3

Acquisition of IriSys - Schedule of Intangible Assets Acquired (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible asset amortized remaining term	6 years 1 month 6 days
Indefinite-lived intangible assets fair value	$ 4,170
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible asset amortized remaining term	7 years
Indefinite-lived intangible assets fair value	$ 3,400
Backlog [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible asset amortized remaining term	2 years 4 months 24 days
Indefinite-lived intangible assets fair value	$ 460
Trademark and tradenames [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible asset amortized remaining term	1 year 6 months
Indefinite-lived intangible assets fair value	$ 310

Acquisition of IriSys - Sched_4

Acquisition of IriSys - Schedule of Supplemental Pro Forma Financial Information (Detail) - Irisys LLC [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Revenue	$ 83,045	$ 78,881
Net loss	$ (11,809)	$ (28,290)

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Money Market Mutual Funds [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Cash equivalents	$ 6,034	$ 15,247

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) Lease	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Lessee Lease Description [Line Items]
Number of operating lease	2
Number of development lease	2
Operating lease, weighted average remaining term	7 years 9 months 18 days
Operating lease, weighted average discount rate percent	14.10%
Total operating lease, cost | $	$ 1,980	$ 814	$ 310
California [Member]
Lessee Lease Description [Line Items]
Operating lease, option to extend	The development facility leases each include options to extend, none of which are included in the lease terms.
Operating lease expiration year	2031
Gainesville, Georgia [Member]
Lessee Lease Description [Line Items]
Operating lease expiration year	2025

Leases - Schedule of Undiscount

Leases - Schedule of Undiscounted Future Lease Payments for the Development Lease (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Lessee Disclosure [Abstract]
2023	$ 1,165
2024	1,193
2025	1,158
2026	1,097
2027	1,127
Thereafter	3,681
Total lease payments	9,421
Less imputed interest	(3,758)
Total operating lease liabilities	$ 5,663

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Aug. 13, 2021
Irisys LLC [Member]
Related Party Transaction [Line Items]
common stock owned percentage	10